The estimated Net Worth of Samuel Bates Martin is at least $3.89 Million dollars as of 14 June 2024. Samuel Martin owns over 20,169 units of Celldex Therapeutics stock worth over $1,886,167 and over the last 6 years Samuel sold CLDX stock worth over $2,004,665.
Samuel has made over 8 trades of the Celldex Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Samuel exercised 20,169 units of CLDX stock worth $204,917 on 14 June 2024.
The largest trade Samuel's ever made was selling 35,000 units of Celldex Therapeutics stock on 30 May 2024 worth over $1,191,750. On average, Samuel trades about 9,070 units every 98 days since 2018. As of 14 June 2024 Samuel still owns at least 45,297 units of Celldex Therapeutics stock.
You can see the complete history of Samuel Martin stock trades at the bottom of the page.
Samuel's mailing address filed with the SEC is 53 I-78 Frontage Rd, Hampton, NJ 08827, USA.
Over the last 16 years, insiders at Celldex Therapeutics have traded over $19,527,314 worth of Celldex Therapeutics stock and bought 273,450 units worth $1,157,166 . The most active insiders traders include Rajesh B Parekh, Garry Arthur Neil, and Inc Medarex. On average, Celldex Therapeutics executives and independent directors trade stock every 69 days with the average trade being worth of $1,750,671. The most recent stock trade was executed by Samuel Bates Martin on 14 June 2024, trading 20,169 units of CLDX stock currently worth $204,917.
celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im
Celldex Therapeutics executives and other stock owners filed with the SEC include: